NASDAQ:SRZN Surrozen - SRZN Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Surrozen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.72 0.00 (0.00%) (As of 01/27/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.72▼$0.7950-Day Range$0.42▼$0.8952-Week Range$0.34▼$3.97Volume409,438 shsAverage Volume753,427 shsMarket Capitalization$25.29 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Surrozen MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.19% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.43Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.46) to ($1.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.31 out of 5 starsMedical Sector308th out of 1,055 stocksBiological Products, Except Diagnostic Industry53rd out of 170 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Surrozen. Previous Next 5.0 Short Interest Percentage of Shares Shorted1.19% of the float of Surrozen has been sold short.Short Interest Ratio / Days to CoverSurrozen has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Surrozen has recently decreased by 18.73%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldSurrozen does not currently pay a dividend.Dividend GrowthSurrozen does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for SRZN. Previous Next 3.0 News and Social Media Coverage News SentimentSurrozen has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.70 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Surrozen this week, compared to 0 articles on an average week.Search InterestOnly 5 people have searched for SRZN on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Surrozen insiders have not sold or bought any company stock.Percentage Held by Insiders29.40% of the stock of Surrozen is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions62.13% of the stock of Surrozen is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Surrozen are expected to grow in the coming year, from ($1.46) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Surrozen is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Surrozen is -0.53, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSurrozen has a P/B Ratio of 0.23. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Surrozen (NASDAQ:SRZN) StockSurrozen, Inc., a biotechnology company, discovers and develops drug candidates to selectively modulate the Wnt pathway for tissue repair and regeneration. It is developing tissue-specific antibodies with application across various disease areas, including diseases of the intestine, liver, retina, cornea, lung, kidney, cochlea, skin, pancreas, and central nervous system. Its products in pipeline include SZN-043 a tissue-specific R-spondin mimetic for the treatment of severe liver disease; and SZN-1326, a bi-specific full-length human antibody that directly modulates Wnt signaling in target tissue by binding to particular Frizzled and LRP receptors that are expressed in intestinal crypts. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.Read More Receive SRZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter. Email Address SRZN Stock News HeadlinesJanuary 4, 2023 | finance.yahoo.comSurrozen to Present at the 41st Annual J.P. Morgan Healthcare ConferenceJanuary 2, 2023 | finance.yahoo.comSurrozen, Inc. (SRZN) Stock Historical Prices & Data - Yahoo FinanceJanuary 28, 2023 | Porter & Company (Ad)Is This The End of Capitalism?EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…December 30, 2022 | finance.yahoo.comSurrozen, Inc. (SRZN) Upgraded to Buy: Here's What You Should KnowDecember 15, 2022 | benzinga.comHow Is The Market Feeling About Surrozen?November 29, 2022 | benzinga.comJP Morgan Downgrades Surrozen to UnderweightNovember 16, 2022 | finance.yahoo.comSurrozen Pauses Early-Stage Ulcerative Colitis Study Due To Liver Associated Adverse EventsNovember 16, 2022 | msn.comPeering Into Surrozen's Recent Short InterestJanuary 28, 2023 | Porter & Company (Ad)The Next Big Crisis Is HereYou just can’t see it yet because it’s NOT a banking, financial, or economic crisis… it’s far worse and threatens every dollar in your retirement account.November 15, 2022 | finance.yahoo.comSurrozen Reports Third Quarter 2022 Financial Results and Provides Corporate UpdateOctober 10, 2022 | finance.yahoo.comSurrozen Presents Data on Two Lead Therapeutic Candidates at United European Gastroenterology (UEG) WeekOctober 6, 2022 | finance.yahoo.comSurrozen Inks Strategic Partnership With Boehringer Ingelheim For Retinal Disease CandidateOctober 4, 2022 | uk.finance.yahoo.comSurrozen, Inc. (SRZN)September 26, 2022 | finance.yahoo.comSurrozen Publishes Study in Translational Vision Science and Technology Demonstrating the Promise of SZN-413 in Preclinical Models of Diabetic RetinopathyAugust 11, 2022 | finance.yahoo.comSurrozen Reports Second Quarter 2022 Financial ResultsJune 27, 2022 | finance.yahoo.comWhat Is The Ownership Structure Like For Surrozen, Inc. (NASDAQ:SRZN)?June 13, 2022 | finance.yahoo.comSurrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-043 for Severe Alcoholic HepatitisMay 24, 2022 | finance.yahoo.comSurrozen Presents Data on Lead Therapeutic Candidates at Digestive Disease Week (DDW)May 18, 2022 | msn.comSurrozen Commences Phase 1 Study of SZN-1326 In Ulcerative ColitisMay 18, 2022 | finance.yahoo.comSurrozen Initiates Dosing in Phase 1 Clinical Trial of SZN-1326 for Moderate to Severe Ulcerative ColitisMay 16, 2022 | finance.yahoo.comSurrozen Publishes Article in Cellular and Molecular Gastroenterology and Hepatology Demonstrating that SZN-1326, a Selective Wnt Mimetic, Stimulated Robust Colon Epithelial Regeneration and Ameliorated Colitis in an Acute Model of Inflammatory Bowel Disease (IBD)May 11, 2022 | finance.yahoo.comSurrozen Reports First Quarter 2022 Financial ResultsMay 5, 2022 | finance.yahoo.comSurrozen to Present at the BofA Securities 2022 Healthcare ConferenceMay 2, 2022 | finance.yahoo.comSurrozen Presents Data Supporting Potential of SZN-413 for the Treatment of Diabetic Retinopathy at the Association for Research in Vision and Ophthalmology (ARVO) Annual MeetingMarch 24, 2022 | finance.yahoo.comSurrozen Reports Fourth Quarter and Full Year 2021 Financial ResultsMarch 10, 2022 | seekingalpha.comCPSH and SRZN among mid-day moversJanuary 14, 2022 | nasdaq.comSurrozen Inc Shares Near 52-Week Low - Market MoverSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive SRZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Surrozen and its competitors with MarketBeat's FREE daily newsletter. Email Address SRZN Company Calendar Last Earnings11/14/2022Today1/28/2023Next Earnings (Estimated)3/23/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:SRZN CUSIPN/A CIK1824893 Webwww.consonancehfw.com Phone650-489-9000FaxN/AEmployees83Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.36) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,650,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-52.89% Return on Assets-44.57% Debt Debt-to-Equity RatioN/A Current Ratio9.56 Quick Ratio9.56 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.13 per share Price / Book0.23Miscellaneous Outstanding Shares35,120,000Free Float24,797,000Market Cap$25.29 million OptionableNot Optionable Beta-0.24 Key ExecutivesMr. Craig C. Parker M.B.A. (Age 61)CEO, Pres & Director Comp: $741.9kMr. Charles Williams (Age 43)Chief Financial Officer Comp: $530.91kDr. Wen-Chen Yeh M.D. (Age 59)Ph.D., Chief Scientific Officer Comp: $528.03kDr. K. Christopher Garcia Ph.D.Co-Founder & Member of Scientific AdvisorDr. Roeland Nusse Ph.D. (Age 73)Co-Founder & Member of Scientific Advisor Dr. Calvin Kuo M.D.Ph.D., Co-Founder & Member of Scientific AdvisorMs. Sheela Mohan-Peterson J.D. (Age 61)M.S., Sr. VP of Legal, Gen. Counsel & Corp. Sec. Dr. Geertrui Vanhove M.B.A. (Age 57)M.D., Ph.D., Chief Medical Officer Dr. Li Yang Ph.D.Sr. VP of BiologyMs. Elizabeth NguyenSr. VP and Head of Talent & CultureMore ExecutivesKey CompetitorsInhibikase TherapeuticsNYSE:IKTFinch Therapeutics GroupNASDAQ:FNCHMicrobot MedicalNASDAQ:MBOTAcorda TherapeuticsNASDAQ:ACORElevation OncologyNASDAQ:ELEVView All CompetitorsInsiders & InstitutionsBoard of Trustees of The Leland Stanford Junior UniversityBought 757,546 shares on 11/15/2022Ownership: 2.227%Vanguard Group Inc.Bought 15,299 shares on 11/15/2022Ownership: 1.387%Empery Asset Management LPSold 41,824 shares on 11/15/2022Ownership: 0.615%BlackRock Inc.Sold 14,500 shares on 11/15/2022Ownership: 0.241%View All Institutional Transactions SRZN Stock - Frequently Asked Questions Should I buy or sell Surrozen stock right now? 3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Surrozen in the last twelve months. There are currently 2 sell ratings and 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "sell" SRZN shares. View SRZN analyst ratings or view top-rated stocks. How have SRZN shares performed in 2023? Surrozen's stock was trading at $0.5819 at the start of the year. Since then, SRZN stock has increased by 23.7% and is now trading at $0.72. View the best growth stocks for 2023 here. Are investors shorting Surrozen? Surrozen saw a drop in short interest during the month of January. As of January 15th, there was short interest totaling 227,300 shares, a drop of 18.7% from the December 31st total of 279,700 shares. Based on an average trading volume of 812,000 shares, the days-to-cover ratio is presently 0.3 days. Approximately 1.2% of the shares of the company are sold short. View Surrozen's Short Interest. When is Surrozen's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023. View our SRZN earnings forecast. How were Surrozen's earnings last quarter? Surrozen, Inc. (NASDAQ:SRZN) released its earnings results on Monday, November, 14th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.05. What is Surrozen's stock symbol? Surrozen trades on the NASDAQ under the ticker symbol "SRZN." How do I buy shares of Surrozen? Shares of SRZN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Surrozen's stock price today? One share of SRZN stock can currently be purchased for approximately $0.72. How much money does Surrozen make? Surrozen (NASDAQ:SRZN) has a market capitalization of $25.29 million. The company earns $-54,650,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis. How can I contact Surrozen? Surrozen's mailing address is 1 PALMER SQUARE SUITE 305, PRINCETON NJ, 08540. The official website for the company is www.consonancehfw.com. The company can be reached via phone at 650-489-9000 or via email at chfw-info@consonancelifesciences.com. This page (NASDAQ:SRZN) was last updated on 1/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.